Promising Research Developments Stir Hopes for Melanoma, Lung, Breast and Ovarian Cancer

The growing excitement about the potential of immunotherapy treatments for cancer continued at the 2015 meeting of the American Association for Cancer Research (AACR), one of the largest cancer research meetings of the year. Several Dana-Farber investigators presented encouraging results of immunotherapy for melanoma, lung cancer, and breast cancer. F. Stephen Hodi, MD, and Leena … Read more

Running Boston: ‘The Only Way I Know How’

By Eric Kaye If you were living under a rock this winter… that is, a rock buried by seven feet of snow like most people around Boston, here is what you might have missed. The Patriots won the Super Bowl, Zayn Malik left One Direction, and Boston set an all-time record for snowfall. Also, somewhere … Read more

Angelina Jolie Puts Spotlight on Genetic Testing and Ovarian Cancer Risk

Once again Angelina Jolie is making headlines after penning another op-ed in The New York Times. The actress shared she has undergone more cancer preventive surgery – this time prophylactic salpingo-oophorectomy, a procedure to have her ovaries and fallopian tubes removed. Two years ago, she wrote about her decision to have a prophylactic double mastectomy, … Read more

Tips for Recovering from a Hysterectomy

Medically reviewed by Ross S. Berkowitz, MD Hysterectomy, the surgical removal of the uterus, may be used to treat a variety of gynecologic cancers, including endometrial (uterine), ovarian, or cervical, or gestational trophoblastic  disease. Like any major surgery, recovering from a hysterectomy, which may also include removal of the ovaries, cervix, and fallopian tubes, takes … Read more

New Drug Combination Shows Promise for Women with Recurrent Ovarian Cancer

For many women with ovarian cancer that has returned after initial treatment, a two-drug combination can significantly extend the time that the disease is kept in check, according to a phase 2 clinical trial led by investigators at the Susan F. Smith Center for Women’s Cancers at Dana-Farber. As reported in Lancet Oncology, researchers compared … Read more

The Latest in Ovarian Cancer Treatment and Research

Although ovarian cancer is often difficult to treat, research continues to yield results that are improving outcomes and quality of life for many patients. “Ovarian cancer research and treatment is exciting today because there are so many resources available and we are no longer committed to just the standard chemotherapy,” says Susana Campos, MD, MPH, … Read more

Dancing for Hope, Friendship and a Cure

If you asked a young Susan Mendoza Friedman where she saw her life going, she would not have said fundraising for cancer research and patient care. But, when the dance studio owner and early childhood expert’s best friend of 40 years, Karen Schek, was diagnosed with ovarian cancer in November 2005, that’s exactly what happened.

Read more

Ask the Expert: Questions and Answers about Ovarian Cancer

Dana-Farber Cancer Institute recently partnered with CancerConnect and Ursula Matulonis, MD, to answer questions about ovarian cancer. Experts in the Susan F. Smith Center for Women’s Cancers offer the latest research and treatment for this type of cancer. Watch one patient’s story.

Q: Is taking curcumin recommended to prevent ovarian cancer from returning? Do you have any other suggestions for preventing recurrence?

Read more

Research in Advanced Ovarian Cancer Shows Promise

By Ursula Matulonis, MD

After a long period of slow progress, new knowledge about the genetics of ovarian cancer is leading to the development and testing of new therapies.

Researchers at the Susan F. Smith Center for Women’s Cancers will soon be launching several phase 3 clinical trials testing drugs known as PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer – tumors that initially responded to platinum-based chemotherapy agents but have shown evidence of regrowth at least six months after treatment. Phase 3 trials test drugs in large numbers of patients to evaluate the drugs’ effectiveness as well as safety. PARP inhibitors work by blocking one of the pathways by which tumor cells repair their damaged DNA.

Read more